文献速递间质性肺疾病

特发性肺纤维化的外部对照:临床试验与真实世界数据源比较

External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究利用历史随机对照试验、多中心登记和电子健康记录数据构建特发性肺纤维化外部对照,并与BMS-986020的II期随机对照试验比较FVC变化率。结果显示,历史RCT安慰剂外部对照的治疗效应点估计值在原试验95%CI内,而登记和电子健康记录外部对照的FVC下降更慢,治疗效应点估计值超出原试验95%CI。

要点

  • 历史RCT安慰剂外部对照可复现原IPF随机对照试验的主要治疗效应
  • 登记和电子健康记录外部对照的FVC下降较安慰剂组更慢,治疗效应不可比
  • RCT来源的外部对照可能作为未来IPF随机对照试验的有用补充

核心结论

  • 由历史RCT安慰剂组构建的IPF外部对照产生与原临床试验可比的主要治疗效应,而真实世界数据来源的外部对照不可比。

研究设计与样本

  • 研究基于适配数据标准构建IPF外部对照,数据来源包括历史随机对照试验、多中心登记(Pulmonary Fibrosis Foundation Patient Registry)和电子健康记录。
  • 采用混合效应模型联合逆概率权重,比较BMS-986020 600 mg每日两次组与BMS安慰剂组及外部对照从基线至26周的FVC变化率。

主要发现

  • 26周时,BMS-986020组FVC变化率为-32.71 ml,BMS安慰剂组为-130.09 ml,差异为97.4 ml(95%CI 24.6-170.2),复现了原BMS-986020随机对照试验结果。
  • RCT外部对照的治疗效应点估计值落在原BMS-986020随机对照试验的95%CI内。
  • 登记外部对照和电子健康记录外部对照的FVC下降速率较BMS安慰剂组更慢,导致治疗效应点估计值超出原BMS-986020随机对照试验的95%CI。

临床怎么用

  • 在IPF随机对照试验设计中,可考虑采用历史RCT安慰剂组构建的外部对照作为补充,但不应直接使用登记或电子健康记录来源的外部对照替代同期对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease for which novel therapies are needed. External controls (ECs) could enhance IPF trial efficiency, but the direct comparability of ECs versus concurrent controls is unknown. Objectives: To develop IPF ECs by fit-for-purpose data standards to historical randomized clinical trial (RCT), multicenter registry (Pulmonary Fibrosis Foundation Patient Registry), and electronic health record (EHR) data and to evaluate endpoint comparability among ECs and the phase II RCT of BMS-986020. Methods: After data curation, the rate of change in FVC from baseline to 26 weeks among participants receiving BMS-986020 600 mg twice daily was compared with the BMS-placebo arm and ECs using mixed-effects models with inverse probability weights. Measurements and Main Results: At 26 weeks, the rates of change in FVC were -32.71 ml for BMS-986020 and -130.09 ml for BMS-placebo (difference, 97.4 ml; 95% confidence interval [CI], 24.6-170.2), replicating the original BMS-986020 RCT. RCT ECs showed treatment effect point estimates within the 95% CI of the original BMS-986020 RCT. Pulmonary Fibrosis Foundation Patient Registry ECs and EHR ECs experienced a slower rate of FVC decline compared with the BMS-placebo arm, resulting in treatment-effect point estimates outside of the 95% CI of the original BMS-986020 RCT. Conclusions: IPF ECs generated from historical RCT placebo arms result in comparable primary treatment effects to that of the original clinical trial, whereas ECs from real-world data sources, including registry or EHR data, do not. RCT ECs may serve as a potentially useful supplement to future IPF RCTs.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Swaminathan AC, Snyder LD, Hong H, et al. External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources. Am J Respir Crit Care Med. 2023. PMID: 37384378. doi:10.1164/rccm.202210-1947OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。